3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Conditions
Ovarian Neoplasms
7
Glioblastoma
4
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rare Tumour
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoadjuvant Therapy
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Locally Advanced Prostate Cancer
1
Limited Stage Small Cell Lung Cancer
1
Hereditary leiomyomatosis and renal cell cancer
1
HER2-negative Breast Cancer
1
Gliosarcoma
1
Glioma
1
For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment
1
Esophageal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinosarcoma
1
Interventions
Specimen Handling
8
Paclitaxel
7
Magnetic Resonance Spectroscopy
6
Carboplatin
6
Biopsy
6
Nivolumab
5
pembrolizumab
3
olaparib
3
X-Rays
3
durvalumab
2
ceralasertib
2
cediranib
2
Taxes
2
Immunoglobulin G
2
trastuzumab deruxtecan
1
sargramostim
1
rucaparib
1
ribociclib
1
rebastinib
1
pelcitoclax
1
pazopanib
1
pamiparib
1
liposomal doxorubicin
1
cobimetinib
1
capivasertib
1
cabozantinib
1
belinostat
1
atezolizumab
1
apatinib
1
Trabectedin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinosarcoma
×
pamiparib
×
Clear all
NCT03933761
2021-08-10
PRECISE
Australia New Zealand Gynaecological Oncology Group
Phase 2
Withdrawn